Inclusion Criteria:

          -  Must weigh at least 35 kilograms (kg).

          -  Histologically or cytologically proven metastatic or locally advanced tumors (with
             measurable disease defined by Response Evaluation Criteria In Solid Tumors [RECIST]
             v1.1), for which no effective standard therapy exists, or where standard therapy has
             failed. Participants must have received at least 1 prior anticancer therapy for the
             indication being considered.

          -  An Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

          -  Life expectancy of ≥ 12 weeks.

          -  Laboratory values meeting protocol criteria.

          -  QT interval corrected for heart rate < 450 msec (using Fridericia's correction), and
             no clinically significant electrocardiographic findings.

        Exclusion Criteria:

          -  Untreated brain or meningeal metastases (participants with history of metastases are
             eligible provided they do not require ongoing steroid treatment and have shown
             clinical and radiographic stability for at least 28 days after definitive therapy).

          -  Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except
             alopecia.

          -  History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.

          -  Recent history (within 6 months) of congestive heart failure (defined as New York
             Heart Association, Class 2 or higher), ischemic cardiovascular event, pericarditis, or
             clinically significant pericardial effusion, cardiac arrythmia or peripheral artery
             disease.

          -  Recent history (within 6 months) of Childs-Pugh B or C classification of liver
             disease.

          -  History of clinically significant medical and/or psychiatric conditions or any other
             reason that, in the opinion of the investigator, would interfere with participation in
             this study or would make the participant an unsuitable candidate to receive study
             drug.

          -  History of uncontrolled, clinically significant endocrinopathy.

          -  Known gastrointestinal disorders making absorption of oral medications problematic.
             Inability to swallow capsules.

          -  If treated with anti-programmed cell death protein-1 (aPD-1)/antiprogrammed cell death
             protein-ligand 1(aPD-L1) targeting or other immunostimulatory agents in the past:
             excluded if had prior pneumonitis, prior Grade 3 or higher immune mediated toxicity,
             hypersensitivity to administered drug or drug related toxicity requiring
             discontinuation.

          -  Active autoimmune disease requiring systemic treatment in past 2-years (exceptions for
             endocrinopathies, vitiligo or atopic conditions)

          -  History of solid organ transplant or allogeneic stem cell transplant.

          -  History of other malignancy, with the following exceptions:

               -  No known active disease present for ≥ 3 years before first dose of study
                  treatment and felt to be at low recurrence by investigator

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

          -  History of interstitial lung disease or pneumonitis.

          -  Major surgery ≤ 28 days prior to first dose of study drug.

          -  Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
             per local testing practices.